ArticleMikrochimica acta2025
Single cell ICP-MS for the assessment of potential nephroprotectors against cisplatin.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The use of cisplatin chemotherapy is often limited by the occurrence of various side effects, with renal toxicity being one of the most serious. In the present work, a single cell ICP-MS (scICP-MS) methodology was optimised to evaluate the cellular uptake of cisplatin in the presence of three potential nephroprotectors such as chitosan-stabilised selenium nanoparticles (Ch-SeNPs), selenomethionine (SeMet) and methionine (Met). Human telomerase reverse transcriptase-immortalised renal proximal tubular epithelial cells (RPTEC/TERT1) and human cervical cancer cells (HeLa) were employed with this aim. In both cell lines, a decrease in the intracellular Pt levels when using SeMet and Met as coadjuvants was revealed, involving less toxicity in renal cells but no reduction in the anticancer effect after measurement of cell viability by MTT assays. In contrast, Ch-SeNPs had no effect on the internalisation of the Pt-drug but enhanced its antitumour efficacy with no additional damage to kidney cells. This would allow decreasing cisplatin doses which would in turn reduce nephrotoxicity risk. Se determination by scICP-MS was also done to study the cell uptake of the selenocompounds, in addition to transmission electron microscopy (TEM) analysis of Ch-SeNPs internalisation. The effects of both SeMet and Ch-SeNPs were confirmed despite the Pt-drug was shown to induce a decrease in cell uptake. Results were compared by two different scICP-MS settings (a conventional introduction system and a special configuration for intact cells), as well as with the classical digestion-based bulk analysis. Our results demonstrate the potential of scICP-MS for metallomic cellular studies to improve cisplatin-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.